Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Charles River Laboratories (CRL)

Charles River Labs signs $510M K.F. (Cambodia) deal; Q4 DSA book-to-bill about 1.1x

Positive Impact 4 of 5 m&a Written later

Charles River Laboratories said at a J.P. Morgan conference that demand for its Discovery and Safety Assessment business improved through the second half of 2025, with a preliminary fourth-quarter book-to-bill of about 1.1x. The company also signed an agreement to buy K.F. (Cambodia) Ltd. for about $510 million and is exercising an option to buy the remaining 79% of PathoQuest SAS for about $60 million, which it expects to help non-GAAP earnings per share.

Key points

  • Preliminary DSA net book-to-bill of approximately 1.1x in Q4 2025; the company says the figure may change once audited 2025 results are complete
  • K.F. (Cambodia) Ltd. purchase price about $510 million, expected to close early in Q1 2026, with accretion of about $0.25 to 2026 and $0.60 to 2027 non-GAAP EPS
  • PathoQuest SAS remaining 79% stake for €51.6 million (about $60 million), expected to close by end of Q1 2026
  • 2026 outlook: top end of organic revenue growth ranges expected to be at least flat; incremental cost savings above $100 million

The filing

CompanyCharles River Laboratories (CRL)
Form8-K, current report
Filed with the SECJan 13, 2026, 8:10 AM ET
Accession number0001628280-26-001905

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:11 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 13, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.